Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Immunoassay Evaluated for Toxoplasmosis

By LabMedica International staff writers
Posted on 25 Apr 2017
The infection by Toxoplasma gondii, an obligate intracellular parasite, is generally benign but can be particularly severe during pregnancy, leading to malformations of the fetus or a series of complications in the newborn.

Currently, there are several analytical systems for the detection of antibodies, with different level of automation, such as Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA) and Enzyme Linked Fluorescent Assay (ELFA) able, depending on the instrument used, to process a large number of samples in a short time.

Microbiologists at the Legnano Hospital examined 301 sera samples from women who came to their center for the routine follow-up in pregnancy and were divided into three groups: Group 1:106 samples from non-immune women; Group 2:100 samples from women with past infection; and Group 3: 95 samples from women with positive or equivocal immunoglobulin M (IgM) (82 with positive IgG and 13 with negative IgG).

The scientists routinely tested samples using chemiluminescence LIAISON XL system for IgG and IgM. In positive subjects for IgM, samples are tested using an ELFA test. All samples were also tested with TGS TA system for detecting IgG and IgM and, for Group 3, IgG avidity (TGS TA Toxoplasma IgG, Toxoplasma IgM, Toxoplasma IgG Avidity.

The overall concordance of the IgG results between LIAISON XL and TGS TA was 99.3%: 100% in Group 1, 98% in Group 2 and 100% in Group 3. The overall concordance of the IgM results between LIAISON XL and TGS TA was 93.9%: 100% in Group 1, 94% in Group 2 and 82.8% in Group 3. In Group 3, the concordance between the results of the IgG avidity with the ELFA and TGS TA tests was 81.7%. Comparing the clinical diagnosis obtained with the protocol and that of the TGS TA system, the overall concordance was 92.7%: 100% in Group 1, 92.0% in Group 2 and 78.9% in Group 3.

The authors concluded that the overall concordance of IgG antibodies is excellent for both protocols. The TGS TA avidity test seems to predict earlier the maturation of the IgG compared to the ELFA test since many samples with low avidity with the ELFA were seen with moderate avidity with TGS TA and all those with borderline avidity with the ELFA were seen with high avidity with TGS TA. This system is shown to be a valuable tool with overall good clinical correlation and able to clearly identify nonspecific subjects, those with a non-recent infection.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.